nefiracetam has been researched along with Disease Models, Animal in 10 studies
*Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farina, C; Gagliardi, S; Ghelardini, C; Martinelli, M; Norcini, M; Parini, C; Petrillo, P; Ronzoni, S | 1 |
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Cao, Y; Chen, Z; Dave, JR; Liao, Z; Lu, XC; Tortella, FC | 1 |
| Chen, M; Duan, CZ; Fu, CY; He, XY; Huang, ZW; Li, J; Li, XF; Zhang, X | 1 |
| Fukunaga, K; Han, F; Moriguchi, S; Nakagawasai, O; Nakajima, T; Narahashi, T; Shioda, N; Tadano, T; Yamamoto, Y; Yeh, JZ | 1 |
| Ando, T; Ichikawa, T; Kajihara, H; Kikuchi, K; Miyake-Takagi, K; Omino, K; Takagi, N; Takeo, S; Tanonaka, K | 1 |
| Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A | 1 |
| Kasai, Y; Kinoshita, M; Kitano, Y; Komiyama, C; Makino, M; Sakurada, S; Takasuna, K; Takazawa, A; Yamauchi, T; Yamazaki, O | 1 |
| Nabeshima, T; Nakamoto, Y; Shiotani, T; Watabe, S; Yoshii, M | 1 |
10 other study(ies) available for nefiracetam and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Imidazoles; Neuralgia; Pain Threshold; Pyrroles; Rats; Structure-Activity Relationship | 2008 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Nefiracetam attenuates post-ischemic nonconvulsive seizures in rats and protects neuronal cell death induced by veratridine and glutamate.
Topics: Animals; Brain; Cell Death; Cell Survival; Cells, Cultured; Disease Models, Animal; Electroencephalography; Epilepsy, Generalized; Infarction, Middle Cerebral Artery; Injections, Intravenous; Male; Neurons; Neuroprotective Agents; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Veratridine | 2013 |
Nefiracetam Attenuates Pro-Inflammatory Cytokines and GABA Transporter in Specific Brain Regions of Rats with Post-Ischemic Seizures.
Topics: Amygdala; Animals; Brain; Brain Ischemia; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; GABA Plasma Membrane Transport Proteins; Hippocampus; Male; Parietal Lobe; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Seizures | 2015 |
Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Denervation; Disease Models, Animal; Enzyme Activation; Hippocampus; Long-Term Potentiation; Male; Memory Disorders; Mice; Nootropic Agents; Olfactory Bulb; Organ Culture Techniques; Phosphorylation; Protein Kinase C; Pyrrolidinones; Receptor, Metabotropic Glutamate 5; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2009 |
Effects of nefiracetam on cerebral adenylyl cyclase activity in rats with microsphere embolism-induced memory dysfunction.
Topics: Animals; Behavior, Animal; Blotting, Western; Body Weight; Brain Ischemia; Cell Membrane; Colforsin; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Embolism; Escape Reaction; GTP-Binding Proteins; Male; Maze Learning; Memory Disorders; Microspheres; Neuroprotective Agents; Pyrrolidinones; Rats; Rats, Wistar; Time Factors | 2003 |
Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electroshock; Levetiracetam; Male; Mice; Nootropic Agents; Pentylenetetrazole; Piracetam; Pyrrolidinones; Rats; Rats, Wistar; Seizures | 2005 |
Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats.
Topics: Administration, Oral; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Electric Stimulation; Electrodes, Implanted; Electroencephalography; Epilepsy, Complex Partial; Humans; Kindling, Neurologic; Levetiracetam; Male; Nootropic Agents; Piracetam; Pyrrolidinones; Rats; Rats, Wistar; Seizures | 2005 |
Anticonvulsant actions of nefiracetam on epileptic EL mice and their relation to peripheral-type benzodiazepine receptors.
Topics: Animals; Anticonvulsants; Benzodiazepinones; Convulsants; Disease Models, Animal; Epilepsy; Male; Mice; Mice, Inbred Strains; Nootropic Agents; Pyrrolidinones; Radioligand Assay; Receptors, GABA-A; Seizures | 2000 |